Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
Article content
CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If confirmed through further testing, the potential of this newly identified group of molecules expands the market potential for Enveric drug candidates in a new direction.
Article content
Neurodegenerative diseases are a heterogenous group of progressive neurological disorders characterized by the gradual loss of neurons, leading to a decline in cognitive, motor and other neurological functions. It has been estimated by the World Health Organization (WHO) that approximately 50 million people worldwide are affected by neurodegenerative diseases, with seven million in the United States.
Article content
Broad claims in the patent application describe a group of molecules that enhance brain derived neurotrophic factor ('BDNF') activity and address conditions where the BDNF/TrKB pathway plays a major role. BDNF and its receptor TrKB support neuroprotection and adult neurogenesis and enhance myelination by increasing the density of oligodendrocyte progenitor cells. While additional pre-clinical testing is needed to confirm the enhancement of BDNF activation, preliminary studies have revealed promotion of neuronal development in a cell-based assay.
Article content
'Based on our team's research, future molecules that emerge from this family could represent therapeutic candidates to develop for Alzheimer's Disease and other neurodegenerative diseases,' said Joseph Tucker, Ph.D., CEO and Director of Enveric. 'In addition to the potential to promote BDNF signaling, an established therapeutic target in neurodegenerative diseases, a prototype molecule from the family has been tested in vivo and revealed encouraging pharmaceutical and pharmacokinetic (PK) characteristics.'
Article content
The preliminary PK profile suggests that the orally delivered compound effectively enters the bloodstream, penetrates the brain, and is subsequently and rapidly cleared from plasma. Further, this molecule did not display 5HT2B receptor activation, which would have been an indicator of cardiovascular risk potential.
Article content
'Based on the discovery and characterization work done to date, we believe further investigation of this family of molecules is warranted,' said Dr. Tucker.
Article content
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development platform Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
Article content
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Ibogaine by David Dardashti Forges Strategic Partnership with Psychedelic University to Cultivate Next-Generation Leaders in Psychedelic Healthcare
MIAMI, FL - June 20, 2025 - Ibogaine by David Dardashti, a pioneering leader in ibogaine-assisted therapy and led by visionary David Dardashti, today announced a groundbreaking collaboration with a Psychedelic University. This strategic partnership aims to establish robust internship opportunities for students passionate about contributing to the rapidly evolving psychedelic field, with initial networking prospects to be explored at the highly anticipated Psychedelic Conference 2025. The initiative is further amplified by the recent opening of Ibogaine by David Dardashti's second state-of-the-art treatment facility, significantly expanding the scope for student involvement. This innovative alliance is designed to bridge the gap between academic learning and practical application, providing students with invaluable hands-on experience in a clinical setting dedicated to transformative healing. The expansion into a second facility dramatically increases Ibogaine by David Dardashti's capacity, creating a diverse array of potential roles for aspiring professionals. "We are incredibly excited to partner with Psychedelic University to nurture the next generation of leaders in psychedelic medicine," said David Dardashti, founder of Ibogaine by David Dardashti. "The opening of our second clinic is not just about expanding our treatment capabilities; it's about building a robust ecosystem where ambitious students can gain real-world experience and help accelerate the growth and acceptance of ibogaine therapy. We believe this collaboration will foster innovation and ethical practices crucial for the future of this field." The internship program will offer multifaceted opportunities for students from various disciplines. Beyond direct clinical exposure, students can expect to engage in critical areas such as: Therapy Options: Assisting in the development and delivery of integrative post-treatment care plans, including counseling and psychological support. Data Collection & Analysis: Contributing to the meticulous gathering and interpretation of patient outcomes, vital for advancing research and validating treatment efficacy. Biomedical Software Development: Participating in the creation and refinement of digital tools designed to enhance patient management, treatment protocols, and research analytics. Marketing Solutions: Developing strategic communication plans to educate the public, destigmatize ibogaine, and expand access to treatment. Meetings will be held in the months following a patient's treatment, creating a unique longitudinal learning environment where interns can observe the full spectrum of patient journeys and recovery. This comprehensive approach ensures that students gain a holistic understanding of patient care, from initial intake to long-term integration support. Representatives from both Ibogaine by David Dardashti and Psychedelic University will be actively engaging with students at the Psychedelic Conference 2025, providing a premier platform for aspiring interns to learn more about these opportunities and network with pioneers in the field. This direct interaction will allow students to present their aspirations and demonstrate their commitment to this burgeoning area of healthcare. The ultimate goal of Ibogaine by David Dardashti is to expand its new clinic with the support of ambitious, dedicated students who are eager to contribute to accelerating the growth and responsible application of ibogaine treatment. This partnership underscores a shared commitment to innovation, education, and the widespread, ethical integration of psychedelic therapies into mainstream healthcare.
CTV News
4 hours ago
- CTV News
Older adults dying from unintentional falls
Older adults dying from unintentional falls A new report shows older adults are dying more from unintentional falls leads MedicalWatch for June 19, 2025.
Vancouver Sun
5 hours ago
- Vancouver Sun
'Swallowing razor blades': What to know about the painful symptom linked to latest COVID strain
A painful symptom that has been linked to the latest strain of COVID-19 is being called 'razor blade throat.' The World Health Organization recently designated NB.1.8.1 as a variant under monitoring . The strain, nicknamed 'Nimbus,' has reportedly been causing extremely painful sort throats in those who have been infected with it. Cases of the Nimbus variant have been rising. It has been detected in 22 countries as of May 18 and made up 10.7 per cent of the global COVID samples taken in late April, WHO said. That was considered a 'significant rise in prevalence' since it only made up 2.5 per cent of global COVID samples four weeks prior. However, WHO deemed the overall risk of Nimbus to be low. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation,' according to WHO. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Here's what to know. Like the name suggests, 'razor blade throat' describes severe sore throat pain, as if the throat is 'covered with razor blades,' chair of the department of medicine and chief of infectious diseases at Mount Sinai South Nassau in New York Dr. Aaron Glatt told . 'While not specific to COVID-19,' he said, 'this expression has been used to describe sore throat symptoms in some patients with the most recent COVID-19 variant.' It has been described by some as 'akin to swallowing shattered glass or razor blades,' news network NTD reported . However, infectious disease specialist at University of California San Francisco Dr. Peter Chin-Hong, told the San Francisco Chronicle that a sore throat from COVID is 'not novel at all.' 'There has been a range of intensity of sore throat with COVID symptoms all along, including very severe pain,' said Chin-Hong. Other symptoms of COVID include runny nose, new or worsening cough, shortness of breath or difficulty breathing, fever, chills, fatigue or weakness, muscle or body aches, new loss of smell or taste, headache, abdominal pain, diarrhea and vomiting. This particular strain 'isn't too different from the Omicron variant , but it does have some tweaks to its spike protein,' according to general practitioner from private healthcare centre Pall Mall Medical in the United Kingdom Dr. Chun Tang, The Independent reported . That means it could 'spread a bit more easily or slip past some of our existing immunity.' 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it,' said Tang. The earliest sample of Nimbus was taken in January, said WHO. In Canada, the federal government has been keeping track of COVID variants detected nationwide. Nimbus was detected in Canada in March, but it only accounted for a very low percentage of COVID strains in the country, at just 0.2 per cent . By the end of May, Nimbus made up roughly 20 per cent of all identified COVID cases. Using earlier trends to estimate the current situation, the government is predicting how variants will spread or diminish. This method is called nowcasting. For the week of June 1, the nowcasted estimates of Nimbus in Canada are predicted to be around 42 per cent. The nowcasted estimates for the week of June 15 jump to 53 per cent, meaning it would make up more than half of the cases in Canada if the prediction is accurate. Other than Canada, Nimbus has been detected around the world, with cases reported in India, Thailand, Hong Kong, Singapore and the United States, according to the World Health Network . It has also made its way to Australia and the United Kingdom .
